Home
Live Updates
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 : comparemela.com
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024
WEXFORD, Pa., Jan. 4, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. , a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dave...
Related Keywords
,
Dave Mehalick ,
Daniel Kontoh Boateng ,
Colleen Delaney ,
Karolinska Institutet ,
David Schemelia ,
Securities Exchange ,
Exchange Commission ,
Karolinska Institute ,
Coeptis Therapeutics Holdings Inc ,
Company Or Coeptis ,
Deverra Therapeutics Inc ,
Prnewswire Coeptis Therapeutics Holdings Inc ,
Holdings Inc ,
Drug Administration ,
Coeptis Therapeutics Holdings ,
Nasdaq ,
University Of Pittsburgh ,
Coeptis Therapeutics Inc ,
Tiberend Strategic Advisors Inc ,
Coeptis Pharmaceuticals Inc ,
Therapeutics Holdings ,
Deverra Therapeutics ,
Chief Scientific ,
Rapidly Advancing Clinical Programs ,
Emerging Leader ,
Natural Killer Cell ,
Gene Meeting ,
Coeptis Therapeutics ,
Coeptis Pharmaceuticals ,
Securities Act ,
Securities Exchange Act ,
Nasdaq Capital Market ,
Strategic Advisors ,
Markets ,
comparemela.com © 2020. All Rights Reserved.